cambridge bioscience corp said received federal drug administration approval its investigational new drug filing human clinical trials its second generation diagnostic test for aids company said anticipates test may released worldwide markets 1987 early 1988 cambridge bioscience also said expects file soon investigational new drug with fda its screening test for detecting aids antibodies this test which being evaluated emergency situations several african nations does not require highly trained technicians nor instrumentation according company cambridge bioscience explained filing for human clinical trials for aids received fda approval utilizes recombinant dna technology detect and screen antibodies blood serum patients infected with aids causing virus separate planned filing with fda revolutionary five minute latex agglutination screening test for detecting aids antibodies company said this test utilizes latex beads coated with cbc recombinant antigen which attract and hold aids antibodies forming clusters agglutination which indicates positive reuter 